Eli Lilly's New Weight-Loss Pill Foundayo Hits U.S. Pharmacies

The pharmaceutical company's latest obesity treatment is now available nationwide.

Apr. 9, 2026 at 2:47pm

Got story updates? Submit your updates here. ›

A translucent, ghostly X-ray image of the human digestive system, with intricate structures glowing in shades of blue, conceptually representing the complex biological mechanisms targeted by weight-loss medications.A new pharmaceutical treatment for obesity aims to suppress appetite and promote weight loss, but its impact remains to be seen.Indianapolis Today

Eli Lilly, the Indianapolis-based pharmaceutical giant, has begun shipping its new weight-loss medication Foundayo to retail pharmacies across the United States. The pill, which received FDA approval last year, is the company's latest offering in the rapidly growing obesity treatment market.

Why it matters

The launch of Foundayo comes at a time when obesity rates in the U.S. continue to rise, with nearly 42% of American adults classified as obese. Effective new treatments could help millions struggling with weight-related health issues, but also raise questions about access, affordability, and the role of pharmaceutical companies in addressing this public health crisis.

The details

Foundayo is a once-daily oral medication that works by suppressing appetite and increasing feelings of fullness. In clinical trials, patients taking Foundayo saw an average weight loss of 15% over a 12-month period. The drug is approved for use in adults with a body mass index (BMI) of 30 or higher, or those with a BMI of 27 or higher who also have weight-related health conditions like type 2 diabetes or high blood pressure.

  • Foundayo received FDA approval in March 2025.
  • Eli Lilly began shipping the medication to U.S. pharmacies in early April 2026.

The players

Eli Lilly

An American pharmaceutical company headquartered in Indianapolis, Indiana, known for developing and manufacturing drugs to treat a wide range of medical conditions.

Foundayo

Eli Lilly's new prescription weight-loss medication that was approved by the FDA in 2025 and is now available nationwide.

Got photos? Submit your photos here. ›

What they’re saying

“Foundayo represents an important new tool in the fight against the obesity epidemic in this country.”

— David Ricks, CEO of Eli Lilly

What’s next

Eli Lilly plans to launch a national marketing campaign to raise awareness of Foundayo and encourage discussions between patients and their healthcare providers about weight management options.

The takeaway

The availability of Foundayo highlights the growing focus on pharmaceutical solutions to address the complex and persistent challenge of obesity in the United States. However, the drug's success will depend on factors like cost, insurance coverage, and the ability to reach the millions of Americans who could potentially benefit from it.